The Michael J. Fox Foundation has awarded a 2.5 million dollar grant to biotech company Neuron23 to expand an innovative Parkinson's clinical trial

The funding is directly supporting the expansion of a Phase 2 study called NEULARK, which focuses on a more tailored approach to medicine. Instead of a one size fits all treatment, this trial looks at the specific biological and genetic markers of the condition to find out who will benefit the most from the therapy. Specifically, the trial is testing an oral drug named NEU-411, which targets a protein called LRRK2. Decades of genetic research suggest that this specific protein plays a critical role in how the condition develops in certain people. The new grant allows four clinical sites to open across Israel, and teams have already screened the very first participant there. This expansion taps into Israel's highly regarded research and clinical community, giving more people with early stage Parkinson's the opportunity to take part. To make things easier and more comprehensive, the trial utilizes digital biomarker technology. This setup means researchers can frequently track and monitor both movement and non movement symptoms over time, giving a much clearer picture of how well the drug works in daily life. The ultimate goal of this collaboration is to shift toward a future where treatments are built around personal biology. By identifying who carries the LRRK2 driven variation early on, scientists hope to fundamentally alter the way the condition is managed and pave the way for highly targeted, personalized therapies.